Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL).
Borlenghi E, Pagani C, Zappasodi P, Bernardi M, Basilico C, Cairoli R, Fracchiolla N, Todisco E, Turrini M, Cattaneo C, Da Vià M, Ciceri F, Passamonti F, Mancini V, Sciumè M, Cerqui E, Sciumè M, Rossi G. Borlenghi E, et al. Among authors: cerqui e. J Geriatr Oncol. 2021 May;12(4):550-556. doi: 10.1016/j.jgo.2020.10.004. Epub 2020 Oct 20. J Geriatr Oncol. 2021. PMID: 33097455
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E, Cattaneo C, Cerqui E, Archetti S, Bertoli D, Bellotti D, Gramegna D, Soverini G, Oberti M, Schieppati F, Pagani C, Passi A, Sciumé M, Farina M, Carbone C, Crippa C, Dalceggio D, Tucci A, Rossi G. Borlenghi E, et al. Among authors: cerqui e. Hematol Oncol. 2020 Dec;38(5):754-762. doi: 10.1002/hon.2806. Epub 2020 Sep 29. Hematol Oncol. 2020. PMID: 32950042
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
Zappasodi P, Marbello L, Borlenghi E, Fumagalli M, Bernardi M, Fracchiolla N, Mancini V, Da Vià M, Ravano E, Cerqui E, Ferretti VV, Rocca B, Calvello C, Cazzola M, Castagnola C, Rossi G. Zappasodi P, et al. Among authors: cerqui e. Ann Hematol. 2018 Nov;97(11):2107-2115. doi: 10.1007/s00277-018-3424-4. Epub 2018 Jul 15. Ann Hematol. 2018. PMID: 30009341 Clinical Trial.
Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome.
Cattaneo C, Gramegna D, Malagola M, Pagani C, Borlenghi E, Cerqui E, Passi A, Sciumé M, Bernardi S, Crippa C, Dalceggio D, Carbone C, Pelizzari AM, Re A, Russo D, Rossi G. Cattaneo C, et al. Among authors: cerqui e. Leuk Lymphoma. 2019 Dec;60(12):3044-3050. doi: 10.1080/10428194.2019.1613535. Epub 2019 May 23. Leuk Lymphoma. 2019. PMID: 31120311
Relapsing bloodstream infections during treatment of acute leukemia.
Cattaneo C, Antoniazzi F, Tumbarello M, Skert C, Borlenghi E, Schieppati F, Cerqui E, Pagani C, Petullà M, Re A, Rossi G. Cattaneo C, et al. Among authors: cerqui e. Ann Hematol. 2014 May;93(5):785-90. doi: 10.1007/s00277-013-1965-0. Epub 2013 Nov 28. Ann Hematol. 2014. PMID: 24288110
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Malagola M, Skert C, Borlenghi E, Chiarini M, Cattaneo C, Morello E, Cancelli V, Cattina F, Cerqui E, Pagani C, Passi A, Ribolla R, Bernardi S, Giustini V, Lamorgese C, Ruggeri G, Imberti L, Caimi L, Russo D, Rossi G. Malagola M, et al. Among authors: cerqui e. Cancer Med. 2016 Feb;5(2):265-74. doi: 10.1002/cam4.593. Epub 2015 Dec 29. Cancer Med. 2016. PMID: 26715369 Free PMC article.
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G. D'Adda M, et al. Among authors: cerqui e. Cancer. 2019 May 15;125(10):1674-1682. doi: 10.1002/cncr.31977. Epub 2019 Feb 1. Cancer. 2019. PMID: 30707758 Free article.
Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Up-A Single Center Experience.
Borlenghi E, Cattaneo C, Bertoli D, Cerqui E, Archetti S, Passi A, Oberti M, Zollner T, Giupponi C, Pagani C, Bianchetti N, Bottelli C, Bagnasco S, Sciumè M, Tucci A, Rossi G. Borlenghi E, et al. Among authors: cerqui e. Cancers (Basel). 2022 Sep 28;14(19):4716. doi: 10.3390/cancers14194716. Cancers (Basel). 2022. PMID: 36230640 Free PMC article.
A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study).
Cattaneo C, Monte S, Algarotti A, Audisio E, Borlenghi E, Campiotti L, Cerqui E, Fanizza C, Giuliani R, Micò C, Rocconi R, Salvi A, Salvi F, Verga L, Levis A, Lambertenghi Deliliers G, Pogliani EM, Tognoni G, Rambaldi A, Rossi G. Cattaneo C, et al. Among authors: cerqui e. J Antimicrob Chemother. 2011 Sep;66(9):2140-5. doi: 10.1093/jac/dkr271. Epub 2011 Jul 5. J Antimicrob Chemother. 2011. PMID: 21729932 Clinical Trial.
21 results